skip to content
Primary navigation


DrugKerendia® (finerenone) [Bayer Healthcare Pharmaceuticals, Inc.]

April 2022

Therapeutic area - Diuretics

Initial approval criteria

  • Patient is 18 years of age or older AND
  • Prescribed by or in consultation with an endocrinologist, cardiologist, or nephrologist AND
  • Patient has the diagnosis of chronic kidney disease and type 2 diabetes AND
  • Patient is currently taking a maximally tolerated angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), unless contraindicated AND
  • Chart notes have been submitted with baseline labs showing all of the following:
    • Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m2 and < 75 mL/min/1.73 m2 AND
    • Urine albumin-to-creatinine ratio ≥ 30 mg/g AND
    • Serum potassium level ≤ 5.0 mEq/L AND
  • Patient is not taking strong CYP3A4 inhibitors concomitantly AND
  • Patient does not have adrenal insufficiency AND
  • Patient does not have severe hepatic impairment (Child-Pugh Class C)
  • Initial approval is for 3 months

Renewal criteria

  • Patient continues to meet initial approval criteria AND
  • Patient has documented disease improvement and/or stabilization AND
  • Patient has documented periodic serum potassium monitoring
  • Renewal approval is for 6 months

Quantity limits

  • Tablets, 10 mg and 20 mg: 34 tablets per 34 days


MHCP Provider Resource Center 651-431-2700 or 800-366-5411

back to top